{"id":"W2327624302","doi":"10.1093/neuonc/nou255.12","title":"ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA","year":2014,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Bevacizumab; Medicine; Clinical endpoint; Internal medicine; Placebo; Oncology; Phases of clinical research; Adverse effect; Gastroenterology; Surgery; Chemotherapy; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001764994,0.001371341,0.003118813,0.0004891479,0.0003291634,0.001111328,0.0009921853,0.001214678,0.005086394],"category_scores_gemma":[0.001201913,0.0006187523,0.001503575,0.0005119687,0.0008124293,0.0008834515,0.0003569883,0.003060993,0.0009605999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008185472,"about_ca_system_score_gemma":0.001561326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00125309,"about_ca_topic_score_gemma":0.003163922,"domain_scores_codex":[0.9994772,0.0003029746,0.00003240516,0.00006453809,0.00004024838,0.00008263197],"domain_scores_gemma":[0.9992837,0.000139531,0.0001606199,0.00006507822,0.00006310871,0.0002879895],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9419583,0.01574525,0.001197886,0.0004281362,0.0009427513,0.00004005762,0.00006273657,0.0005845873,0.00441243,0.0001145265,0.001204799,0.03330838],"study_design_scores_gemma":[0.7994266,0.1935141,0.003168689,0.000034887,0.0004840847,0.00009314901,0.00002839633,0.0007165342,0.000868735,0.0001708837,0.00147364,0.00002034498],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892033,0.002599015,0.0005309266,0.0004131605,0.0002807757,0.003182394,0.00110756,0.0001178693,0.002564981],"genre_scores_gemma":[0.9828334,0.00259455,0.001543974,0.001011209,0.0002959474,0.004361477,0.00251327,0.00004220434,0.004803913],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005086394,"threshold_uncertainty_score":0.0170157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02235071206839599,"score_gpt":0.3150840269654915,"score_spread":0.2927333148970955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}